FDA approves Novartis' meningitis B vaccine

FDA approved Bexsero from Novartis AG (NYSE:NVS; SIX:NOVN) to prevent invasive meningococcal disease caused by serogroup B in individuals aged 10-25. The multicomponent meningococcal serogroup B vaccine had breakthrough therapy designation in the U.S. and had already been approved under a treatment IND in the U.S. as part of vaccination programs at two universities.

Bexsero is slated to launch this quarter. Spokesperson Elizabeth Power said Novartis will announce a price in about two weeks. ...